Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 2
1988 3
1989 2
1990 7
1991 9
1992 14
1993 25
1994 23
1995 32
1996 80
1997 91
1998 126
1999 150
2000 154
2001 145
2002 195
2003 203
2004 220
2005 269
2006 287
2007 293
2008 312
2009 318
2010 310
2011 371
2012 348
2013 339
2014 315
2015 288
2016 275
2017 279
2018 263
2019 252
2020 287
2021 280
2022 242
2023 234
2024 77

Text availability

Article attribute

Article type

Publication date

Search Results

6,368 results

Results by year

Filters applied: . Clear all
Page 1
Alendronate sodium.
Ananchenko G, Novakovic J, Tikhomirova A. Ananchenko G, et al. Profiles Drug Subst Excip Relat Methodol. 2013;38:1-33. doi: 10.1016/B978-0-12-407691-4.00001-0. Profiles Drug Subst Excip Relat Methodol. 2013. PMID: 23668401 Review.
This chapter is a review on physical and chemical properties, methods of preparation, analysis, as well as pharmacodynamics and pharmacokinetics of Alendronate sodium (4-amino-1-hydroxybutane-1,1-diphosphonic acid sodium salt), a bone metabolism regulator, indicated for th …
This chapter is a review on physical and chemical properties, methods of preparation, analysis, as well as pharmacodynamics and pharmacokine …
Alendronate/colecalciferol.
Reynolds NA, Curran MP. Reynolds NA, et al. Treat Endocrinol. 2005;4(6):371-7; discussion 379. doi: 10.2165/00024677-200504060-00006. Treat Endocrinol. 2005. PMID: 16318403 Review.
The mean oral bioavailability of alendronate or colecalciferol is similar when administered alone or as one once-weekly tablet containing alendronate/colecalciferol 70 mg/2800 IU. In a 15-week, randomized, double-blind, multicenter study in patients with osteoporosi …
The mean oral bioavailability of alendronate or colecalciferol is similar when administered alone or as one once-weekly tablet contai …
Alendronate--a new bisphosphonate.
Selby PL. Selby PL. Osteoporos Int. 1996;6 Suppl 2:21-3. doi: 10.1007/BF01625238. Osteoporos Int. 1996. PMID: 8883133 Review. No abstract available.
Pharmacokinetics of alendronate.
Porras AG, Holland SD, Gertz BJ. Porras AG, et al. Clin Pharmacokinet. 1999 May;36(5):315-28. doi: 10.2165/00003088-199936050-00002. Clin Pharmacokinet. 1999. PMID: 10384857 Review.
Alendronate (alendronic acid; 4-amino-1-hydroxybutylidene bisphosphonate) has demonstrated effectiveness orally in the treatment and prevention of postmenopausal osteoporosis, corticosteroid-induced osteoporosis and Paget's disease of the bone. ...Preclinically, …
Alendronate (alendronic acid; 4-amino-1-hydroxybutylidene bisphosphonate) has demonstrated effectiveness orally in the treatme …
Alendronate: an update of its use in osteoporosis.
Sharpe M, Noble S, Spencer CM. Sharpe M, et al. Drugs. 2001;61(7):999-1039. doi: 10.2165/00003495-200161070-00010. Drugs. 2001. PMID: 11434454 Review.
Alendronate (alendronic acid) is a nitrogen-containing bisphosphonate which binds to bone surfaces and inhibits bone resorption by osteoclasts. ...In clinical trials, alendronate was generally well tolerated when taken as recommended. ...
Alendronate (alendronic acid) is a nitrogen-containing bisphosphonate which binds to bone surfaces and inhibits bone resorptio …
Alendronate for the treatment of osteoporosis in men.
Olszynski WP, Davison KS. Olszynski WP, et al. Expert Opin Pharmacother. 2008 Feb;9(3):491-8. doi: 10.1517/14656566.9.3.491. Expert Opin Pharmacother. 2008. PMID: 18220499 Review.
Fracture-related morbidity and mortality in men is substantially higher than in women. OBJECTIVE: To investigate alendronate for treating osteoporosis in men. METHODS: Search limited to 'men' and 'English'; keywords were 'osteoporosis' or 'bone density' or 'fracture' and ' …
Fracture-related morbidity and mortality in men is substantially higher than in women. OBJECTIVE: To investigate alendronate for trea …
Alendronate and fusion.
Fehlings MG, Mobasheri R. Fehlings MG, et al. J Neurosurg Spine. 2011 Apr;14(4):497-8; discussion 498-9. doi: 10.3171/2010.9.SPINE10525. Epub 2011 Jan 28. J Neurosurg Spine. 2011. PMID: 21275556 No abstract available.
Alendronate in the treatment of osteoporosis: a review of the clinical trials.
Siris E. Siris E. J Womens Health Gend Based Med. 2000 Jul-Aug;9(6):599-606. doi: 10.1089/15246090050118125. J Womens Health Gend Based Med. 2000. PMID: 10957748 Review.
Alendronate is also effective for preventing bone loss in early postmenopausal women. Thus, alendronate represents an important option for preventing and treating this common and debilitating disease. ...
Alendronate is also effective for preventing bone loss in early postmenopausal women. Thus, alendronate represents an importan …
Alendronate prolongs the reversal-resorption phase in human cortical bone remodeling.
Borggaard XG, Roux JP, Delaisse JM, Chavassieux P, Andreasen CM, Andersen TL. Borggaard XG, et al. Bone. 2022 Jul;160:116419. doi: 10.1016/j.bone.2022.116419. Epub 2022 Apr 10. Bone. 2022. PMID: 35413490 Free article.
In this study, the cortical bone remodeling in human iliac bone specimens of 65 non-treated and 24 alendronate-treated osteoporotic women was investigated using a new histomorphometric classification of intracortical pores. ...Importantly, these differences between alen …
In this study, the cortical bone remodeling in human iliac bone specimens of 65 non-treated and 24 alendronate-treated osteoporotic w …
Alendronate-induced asthma.
Isik A, Uras I, Uyar ME, Karakurt F, Kaftan O. Isik A, et al. Ann Pharmacother. 2009 Mar;43(3):547-8. doi: 10.1345/aph.1L552. Epub 2009 Mar 3. Ann Pharmacother. 2009. PMID: 19261958 No abstract available.
6,368 results